Skip to main content
. Author manuscript; available in PMC: 2014 Aug 1.
Published in final edited form as: Mol Cancer Ther. 2013 May 30;12(8):1504–1514. doi: 10.1158/1535-7163.MCT-12-1197

Figure 4.

Figure 4

Vinblastine does not enhance ABT-737 toxicity to normal lymphocytes or platelets. (A) Freshly-isolated lymphocytes from normal donors were incubated with 0.1 μM ABT-737, 1 μM vinblastine or a combination of both drugs for 6 h. Apoptosis was scored by chromatin condensation with the percentage of cells surviving shown. Standard error bars are shown (n=10). * p value < 0.05 compared to control. (B) Freshly-isolated platelets from cancer-free patients were incubated with 0–10 μM ABT-737 with or without 1 μM vinblastine for 6 h. Cell lysates were analyzed for protein expression, and gelsolin cleavage was used as a marker for platelet apoptosis. A representative sample from 3 experiments is shown.